FDG-PET imaging for Hodgkin lymphoma: Current use and future applications

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 1, 2014, Pages 20-35

  Kostakoglu, Lale ^a   Evens, Andrew M ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Contrastenhanced computed tomography; F fluorodeoxyglucose positron emission tomography; Hodgkin lymphoma; Response adapted

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE;

ARTICLE; BONE MARROW BIOPSY; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; HODGKIN DISEASE; META ANALYSIS (TOPIC); NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); TUMOR GROWTH; TUMOR VOLUME; DIAGNOSTIC USE; HUMAN; PATHOLOGY; PROCEDURES; PROGNOSIS;

FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84892964807     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630-1636.
2. Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004;45(1):85-92.
3. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer. 2004;90(3):620-625.
4. Hutchings M, Loft A, Hansen M, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica. 2006;91(4):482-489.
5. Rigacci L, Vitolo U, Nassi L, et al; Intergruppo Italiano Linfomi. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol. 2007;86(12):897-903.
6. Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol. 2007;78(3):206-212.
7. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104(5):1066-1074.
8. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998;206(2):475-481.
9. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Radiology. 2004;232(3):823-829.
10. Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing wholebody dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46(4):608-613.
11. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008;111(2):504-516.
12. Cerci JJ, Trindade E, Buccheri V, et al. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions. Clin Lymphoma Myeloma Leuk. 2011;11(4):314-320.
13. Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol. 2002;81(1):20-25.
14. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica. 2001;86(3):266-273.
15. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol. 1998;9(10):1117-1122.
16. Raanani P, Shasha Y, Perry C, et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol. 2006;17(1):117-122.
17. Rodríguez-Vigil B, Gómez-León N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47(10):1643-1648.
18. Pinilla I, Gómez-León N, Del Campo-Del Val L, et al. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma. Q J Nucl Med Mol Imaging. 2011;55(5):567-575.
19. Elstrom RL, Leonard JP, Coleman M, Brown RK. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol. 2008;19(10):1770-1773.
20. Gollub MJ, Hong R, Sarasohn DM, Akhurst T. Limitations of CT during PET/CT. J Nucl Med. 2007;48(10):1583-1591.
21. Chalaye JLA, Luciani A, Meignan M, et al. Clinical impact of contrastenhanced computed tomography (CECT) combined with low-dose FDG PET/ CT on lymphoma patient management. J Nucl Med. 2012;53(suppl 1):1369.
22. Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Højgaard L. PET/ CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging. 2005;32(10):1167-1175.
23. Beyer T, Antoch G, Bockisch A, Stattaus J. Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med. 2005;46(3):429-435.
24. Mawlawi O, Erasmus JJ, Munden RF, et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol. 2006;186(2):308-319.
25. Ansquer C, Hervouet T, Devillers A, et al. 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. Haematologica. 2008;93(1):128-131.
26. Friedberg JW, Diehl V. Non-Hodgkin's lymphomas. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Devita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:2098-2166.
27. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46(6):958-963.
28. Wu LM, Chen FY, Jiang XX, Gu HY, Yin Y, Xu JR. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis. Eur J Radiol. 2012;81(2):303-311.
29. El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508-4514.
30. Gospodarowicz MK, Ferry JA, Cavalli F. Unique aspects of primary extranodal lymphomas. In: Mauch PM, Armitage JO, Harris NL, Dalla-Favera R, Coiffier B, eds. Non-Hodgkin's Lymphomas. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:685-707.
31. Picardi M, Soricelli A, Grimaldi F, Nicolai E, Gallamini A, Pane F. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. Ann Oncol. 2011;22(3):671-680.
32. Girinsky T, Ghalibafian M. Radiotherapy of hodgkin lymphoma: indications, new fields, and techniques. Semin Radiat Oncol. 2007;17(3):206-222.
33. Dühmke E, Franklin J, Pfreundschuh M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol. 2001;19(11):2905-2914.
34. Engert A, Schiller P, Josting A, et al; German Hodgkin's Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601-3608.
35. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006;24(19):3128-3135.
36. Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002;94(6):1731-1738.
37. Meyer RM, Gospodarowicz MK, Connors JM, et al; Eastern Cooperative Oncology Group. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634-4642.
38. Meyer RM, Gospodarowicz MK, Connors JM, et al; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366(5):399-408.
39. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
40. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50(8):1257-1260.
41. Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53(10):1876-1881.
42. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10):1824-1833.
43. Juweid ME, Stroobants S, Hoekstra OS, et al; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578.
44. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
45. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;23(21):4652-4661.
46. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160-1168.
47. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-59.
48. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91(4):475-481.
49. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746-3752.
50. Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging. 2011;38(6):1064-1071.
51. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54(5):683-690.
52. Kostakoglu L, Schoder H, Hall N, et al. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma. 2012;53(11):2143-2145.
53. Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy vs no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD: results of the UK NCRI RAPID trial [ASH abstract 547]. Blood. 2012;120(21).
54. Engert A, Haverkamp H, Kobe C, et al; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791-1799.
55. Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dosereduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199-4206.
56. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006;17(8):1296-1300.
57. Zinzani PL, Rigacci L, Stefoni V, et al. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39(1):4-12.
58. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906-1914.
59. Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51(9):1337-1343.
60. Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011;22(4):910-915.
61. Filippi AR, Botticella A, Bellò M, et al. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leuk Lymphoma. 2013;54(6):1183-1187.
62. Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid-and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009;20(11):1848-1853.
63. Straus DJ, Johnson JL, LaCasce AS, et al; Cancer and Leukemia Group B. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117(20):5314-5320.
64. Clinicaltrials. gov. Fludeoxyglucose F 18 PET scan-guided therapy or standard therapy in treating patients with previously untreated stage I or stage II Hodgkin's lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT00433433. Identifier: NCT00433433. Accessed August 22, 2013.
65. Clinicaltrials. gov. HD16 for early stage Hodgkin lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT00736320. Identifier: NCT00736320. Accessed August 22, 2013.
66. Clinicaltrials. gov. HD17 for intermediate stage Hodgkin lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT01356680. Identifier: NCT01356680. Accessed August 22, 2013.
67. Clinicaltrials. gov. Chemotherapy based on positron emission tomography scan in treating patients with stage I or stage II Hodgkin lymphoma. http://www. clinicaltrials.gov/ct2/show/NCT01132807. Identifier: NCT01132807. Accessed August 22, 2013.
68. Clinicaltrials. gov. Response-based therapy assessed by PET scan in treating patients with bulky stage I and stage II classical Hodgkin lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT01118026. Identifier: NCT01118026. Accessed August 22, 2013.
69. Gallamini A, Patti C, Viviani S, et al. Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2011;152:551-560.
70. Markova J, Kahraman D, Kobe C, et al. Role of [18F]-fluoro-2-deoxy-Dglucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma. 2012;53(1):64-70.
71. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood. 2007;109(3):905-909.
72. Dann EJ, Blumenfeld Z, Bar-Shalom R, et al. A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved. Am J Hematol. 2012;87(1):32-36.
73. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol. 2010;21(1):126-132.
74. Press OW, LeBlanc M, Rimsza LM, et al. A phase II trial of response adapted therapy of stage III-IV Hodgkin lymphoma using early interim FDG-PET imaging. [ICML abstract 124]; Hematol Oncol. 2013;31(suppl 1).
75. Clinicaltrials. gov. Combination chemotherapy and radiation therapy in treating young patients with newly diagnosed Hodgkin lymphoma. http://www. clinicaltrials.gov/ct2/show/NCT01026220. Identifier: NCT01026220. Accessed August 22, 2013.
76. Clinicaltrials. gov. Fludeoxyglucose F 18-PET/CT imaging in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma (RATHL). http://www.clinicaltrials.gov/ct2/show/NCT00678327. Identifier: NCT00678327. Accessed August 22, 2013.
77. Clinicaltrials. gov. Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin Lymphoma (HL) (HD0607). http://www.clinicaltrials.gov/ ct2/show/NCT00795613. Identifier: NCT00795613. Accessed August 22, 2013.
78. Clinicaltrials. gov. High-dose chemotherapy and stem cell transplantation, in patients PET-2 positive, after 2 courses of ABVD and comparison of RT versus no RT in PET-2 negative patients (HD0801). http://www.clinicaltrials.gov/ct2/show/NCT00784537. Identifier: NCT00784537. Accessed August 22, 2013.
79. Clinicaltrials. gov. HD18 for advanced stages in Hodgkin's lymphoma. http:// www.clinicaltrials.gov/ct2/show/NCT00515554. Identifier: NCT 00515554. Accessed August 22, 2013.
80. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112(10):3989-3994.
81. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652.
82. Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica. 2007;92(6):771-777.
83. Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2008;111(4):2339-2346.
84. Spaepen K, Stroobants S, Dupont P, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003;30(5):682-688.
85. Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Ann Oncol. 2005;16(9):1524-1529.
86. Hatt M, Cheze le Rest C, Descourt P, Dekker A, De Ruysscher D, et al. Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys. 2010;77(1):301-308.
87. Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38(7):1191-1202.
88. Werner-Wasik M, Nelson AD, Choi W, et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. 2012;82(3):1164-1171.
89. Kostakoglu L, Gandikota N, Hutching M, et al. Deauville criteria and postone cycle SUVmax decrease seems to predict progression free survival better than metabolic tumor measurements in classical Hodgkin's lymphoma [EANM abstract]. Eur J Nucl Med Mol Imaging. 2012;39(suppl):S155.
90. Tseng D, Rachakonda LP, Su Z, et al. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease. Radiat Oncol. 2012;7(1):5.
91. Watabe T, Tatsumi M, Watabe H, et al. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT. Ann Nucl Med. 2012;26(3):222-227.
92. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008;49(Suppl 2):64S-80S.
93. Shields AF. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med. 2003;44(9):1432-1434.
94. Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med. 2009;50:1102-1109.
95. Been LB, Suurmeijer AJ, Cobben DC, et al. [18F]FLT-PET in oncology: current status and opportunities Eur J Nucl Med. Mol Imaging. 2004;31:1659-1672.
96. Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66(22):11055-11061.
97. Buchmann I, Neumaier B, Schreckenberger M, Reske S. [18F]3r-deoxy-3-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study. Cancer Biother Radiopharm. 2004;19(4):436-442.
98. Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 33-deoxy-3--[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13(12):3552-3558.
99. Herrmann K, Buck AK, Schuster T, et al. A pilot study to evaluate 39-deoxy-33-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. J Nucl Med. 2011;52(12):1898-1902.
100. Johnston C, Brennan S, Ford S, Eustace S. Whole body MR imaging: applications in oncology. Eur J Surg Oncol. 2006;32(3):239-246.
101. Attariwala R, Picker W. Whole body MRI: improved lesion detection and characterization with diffusion weighted techniques. J Magn Reson Imaging. 2013;38(2):253-268.
102. Vermoolen MA, Kersten MJ, Fijnheer R, van Leeuwen MS, Kwee TC, Nievelstein RA. Magnetic resonance imaging of malignant lymphoma. Expert Rev Hematol. 2011;4(2):161-171.
103. Punwani S, Prakash V, Bainbridge A, et al. Quantitative diffusion weighted MRI: a functional biomarker of nodal disease in Hodgkin lymphoma? Cancer Biomark. 2010;7(4):249-259.
104. Abdulqadhr G, Molin D, Aström G, et al. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol. 2011;52(2):173-180.
105. van Ufford HM, Kwee TC, Beek FJ, et al. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR Am J Roentgenol. 2011;196(3):662-669.
106. De Paepe K, Bevernage C, De Keyzer F, et al. Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study. Cancer Imaging. 2013;13(1):53-62.
107. Jiang XX, Yan ZX, Song YY, Zhao WL. A pooled analysis of MRI in the detection of bone marrow infiltration in patients with malignant lymphoma. Clin Radiol. 2013;68(3):e143-e153.
108. Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol. 2011;197(3):W384-91.
109. Kwee TC, van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol. 2009;44(10):683-690.
110. Wu X, Nerisho S, Dastidar P, et al. Comparison of different MRI sequences in lesion detection and early response evaluation of diffuse large B-cell lymphoma--a whole-body MRI and diffusion-weighted imaging study. NMR Biomed. 2013;26(9):1186-1194.
111. Adams HJ, Kwee TC, Vermoolen MA, et al. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol. 2013;23(8):2271-2278.